Carisma Therapeutics Stock Revenue
| CARM Stock | 0.85 0.01 1.19% |
Carisma Therapeutics fundamentals help investors to digest information that contributes to Carisma Therapeutics' financial success or failures. It also enables traders to predict the movement of Carisma Stock. The fundamental analysis module provides a way to measure Carisma Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Carisma Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 14.9 M | 11.9 M |
Carisma | Revenue |
Carisma Therapeutics Company Revenue Analysis
Carisma Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Carisma Therapeutics Revenue | 14.92 M |
Most of Carisma Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Carisma Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Carisma
Projected quarterly revenue analysis of Carisma Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Carisma Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Carisma Therapeutics' stock price.
Carisma Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Carisma Therapeutics is extremely important. It helps to project a fair market value of Carisma Stock properly, considering its historical fundamentals such as Revenue. Since Carisma Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Carisma Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Carisma Therapeutics' interrelated accounts and indicators.
| 0.27 | 0.05 | 0.28 | 0.41 | 0.28 | ||
| 0.27 | 0.19 | -0.09 | 0.19 | 0.63 | ||
| 0.05 | 0.19 | 0.07 | -0.11 | 0.18 | ||
| 0.28 | -0.09 | 0.07 | 0.78 | -0.11 | ||
| 0.41 | 0.19 | -0.11 | 0.78 | 0.21 | ||
| 0.28 | 0.63 | 0.18 | -0.11 | 0.21 |
Click cells to compare fundamentals
Carisma Revenue Historical Pattern
Today, most investors in Carisma Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Carisma Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Carisma Therapeutics revenue as a starting point in their analysis.
Carisma Therapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Carisma Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Carisma Therapeutics reported 14.92 M of revenue. This is 99.8% lower than that of the Biotechnology sector and 97.99% lower than that of the Health Care industry. The revenue for all United States stocks is 99.84% higher than that of the company.
Carisma Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Carisma Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Carisma Therapeutics could also be used in its relative valuation, which is a method of valuing Carisma Therapeutics by comparing valuation metrics of similar companies.Carisma Therapeutics is currently under evaluation in revenue category among its peers.
Carisma Fundamentals
| Return On Equity | -3.63 | ||||
| Return On Asset | -0.56 | ||||
| Operating Margin | (3.88) % | ||||
| Current Valuation | 12.1 M | ||||
| Shares Outstanding | 41.75 M | ||||
| Shares Owned By Insiders | 28.53 % | ||||
| Shares Owned By Institutions | 31.51 % | ||||
| Number Of Shares Shorted | 558.58 K | ||||
| Price To Book | 114.10 X | ||||
| Price To Sales | 1.76 X | ||||
| Revenue | 14.92 M | ||||
| EBITDA | (85.89 M) | ||||
| Net Income | (86.88 M) | ||||
| Total Debt | 3.12 M | ||||
| Book Value Per Share | (0.27) X | ||||
| Cash Flow From Operations | (81.18 M) | ||||
| Short Ratio | 3.11 X | ||||
| Earnings Per Share | (1.52) X | ||||
| Target Price | 9.8 | ||||
| Number Of Employees | 107 | ||||
| Market Capitalization | 35.65 M | ||||
| Total Asset | 89.55 M | ||||
| Retained Earnings | (245.1 M) | ||||
| Working Capital | 64.56 M | ||||
| Net Asset | 89.55 M |
About Carisma Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Carisma Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carisma Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carisma Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Carisma Therapeutics Piotroski F Score and Carisma Therapeutics Altman Z Score analysis. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.